Small Cell Lung Cancer
Advertisement
The results of the phase 3 NRG Oncology/Alliance LU005 trial were presented during the 2024 ASTRO Annual Meeting.
Dr. Li discusses important thoracic oncology data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
Dr. Halmos weighs in on HARMONi-2, TROPION-Lung 01, the SOHO-01 and Beamion LUNG-1 studies, and more.
Martin Reck, MD, PhD, shares his insights on key data in lung cancer to be presented at the ESMO Congress 2024.
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
Researchers used data from the Thoracic Tumors Registry to conduct 2 analyses using artificial intelligence.
The intervention included psychoeducation, relaxation training, and behavioral techniques for managing acute breathlessness.
Dr. Reck discusses why the research represents important progress in treating patients with extensive-stage SCLC.
Eric Singhi, MD, shares what he's most looking forward to at the upcoming ISALC 2024 World Conference on Lung Cancer.
Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego.
Learn how clinicians can take practical steps to ensure patients with lung cancer receive comprehensive biomarker testing.
The trial has been discontinued based on the recommendations of an independent data monitoring committee.
The initiation of the trial is based on updated results from a subgroup analysis of the phase 1/2 IDeate-PanTumor01 trial.
Recent data show that less than half of patients are receiving biomarker testing results before starting treatment.
The regulatory action is based on data from the phase 3 ADRIATIC trial.
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
Trilaciclib is an FDA-approved agent that protects hematopoietic stem cells from chemotherapy-induced myelosuppression.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.